Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Neutralizing antibodies (NAbs) to interferon beta (IFN-beta) can impact treatment efficacy in multiple sclerosis (MS).
• Increasing the IFN-beta dose may reduce NAb occurrence.
• The OPTIMization of Interferon for MS (OPTIMS) study compared approved (250 mcg) and higher (375 mcg) subcutaneous IFN-beta-1b doses.

Purpose of the Study:

• To analyze the long-term (4-year) occurrence of NAbs and their impact on clinical and MRI response in MS patients.
• To evaluate the effectiveness of a higher IFN-beta-1b dose in reducing NAbs.

Main Methods:

• A multicenter trial involving 145 relapsing-remitting MS patients.
• Open-label assessment of relapses and disease progression.
• Serial MRI scans and MxA protein production neutralization assay for NAb measurement.

Main Results:

• NAb frequency was negatively associated with MRI treatment response, but not clinical response.
• Patients receiving 375 mcg IFN-beta-1b showed a significantly higher probability of NAb disappearance over 4 years (HR: 3.41).
• Cross-sectional and longitudinal analyses yielded similar outcomes.

Conclusions:

• A higher dose of IFN-beta-1b (375 mcg) increases the likelihood of NAb disappearance in MS patients.
• The OPTIMS study provides evidence for dose optimization in managing NAbs during IFN-beta-1b therapy.
• The study was registered at ClinicalTrials.gov (NCT00473213).